Evidence map›Paper›PMID 29857547›Full record

Observational studyNutrients2018

Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS HEPAVIH CO-13 Cohort).

Issifou Yaya, Fabienne Marcellin, Marie Costa, Philippe Morlat, Camelia Protopopescu, Gilles Pialoux, Melina Erica Santos, Linda Wittkop, Laure Esterle, Anne Gervais and 4 more

Open access · goldAbstract readComparative StudyMulticenter StudyObservational Study
In one paragraph

Observational study in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Issifou YayaINSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Aix Marseille Université, 27 Bd Jean Moulin, 13005 Marseille, France. issifou.yaya@inserm.fr.
Fabienne MarcellinINSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Aix Marseille Université, 27 Bd Jean Moulin, 13005 Marseille, France. fabienne.marcellin@inserm.fr.
Marie CostaINSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Aix Marseille Université, 27 Bd Jean Moulin, 13005 Marseille, France. marie.costa@inserm.fr.ORCID 0000-0001-7360-1921
Philippe MorlatService de Médecine Interne, Hôpital Saint André, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, 1 Rue Jean Burguet, 33000 Bordeaux, France. philippe.morlat@chu-bordeaux.fr.
Camelia ProtopopescuINSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Aix Marseille Université, 27 Bd Jean Moulin, 13005 Marseille, France. camelia.protopopescu@inserm.fr.
Gilles PialouxDépartement des Maladies Infectieuses, Hôpital Tenon, 4, rue de la Chine, 75020 Paris, France. gilles.pialoux@aphp.fr.
Melina Erica SantosMinistério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância, Prevenção e Controle das IST, do HIV/Aids e das Hepatites Virais, Brasília 70719-040, Brazil. melinabtu@gmail.com.
Linda WittkopISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, Université Bordeaux, F-33000 Bordeaux, France. linda.wittkop@u-bordeaux.fr.
Laure EsterleFaculdade de Ciências da Saúde, Programa de Pós-Graduação em Saúde Coletiva, Universidade de Brasília, Brasília 70910-900, Brazil. laure.esterle@u-bordeaux.fr.ORCID 0000-0002-1017-1327
Anne GervaisService des Maladies Infectieuses et Tropicales, AP-HP, Hôpital Bichat Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France. anne.gervais@aphp.fr.
Philippe SogniINSERM U-1223, Institut Pasteur, Service d'Hépatologie, Hôpital Cochin, Université Paris Descartes, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France. philippe.sogni@aphp.fr.
Dominique Salmon-CeronService Maladies Infectieuses et Tropicales, AP-HP, Hôpital Cochin, Université Paris Descartes, 27 rue du Faubourg-Saint-Jacques, 75014 Paris, France. dominique.salmon@aphp.fr.
Maria Patrizia CarrieriINSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Aix Marseille Université, 27 Bd Jean Moulin, 13005 Marseille, France. maria-patrizia.carrieri@inserm.fr.
ANRS CO13-HEPAVIH Cohort Study Group
Inserm · FRUniversidade de Brasília · BRSorbonne Université · FRUniversité Claude Bernard Lyon 1 · FRUniversité de Bordeaux · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoffee intake has been shown to modulate both the effect of ethanol on serum GGT activities in some alcohol consumers and the risk of alcoholic cirrhosis in some patients with chronic diseases. This study aimed to analyze the impact of coffee intake and alcohol consumption on advanced liver fibrosis (ALF) in HIV-HCV co-infected patients.

methodsANRS CO13-HEPAVIH is a French, nationwide, multicenter cohort of HIV-HCV-co-infected patients. Sociodemographic, behavioral, and clinical data including alcohol and coffee consumption were prospectively collected using annual self-administered questionnaires during five years of follow-up. Mixed logistic regression models were performed, relating coffee intake and alcohol consumption to ALF.

results1019 patients were included. At the last available visit, 5.8% reported high-risk alcohol consumption, 27.4% reported high coffee intake and 14.5% had ALF. Compared with patients with low coffee intake and high-risk alcohol consumption, patients with low coffee intake and low-risk alcohol consumption had a lower risk of ALF (aOR (95% CI) 0.24 (0.12–0.50)). In addition, patients with high coffee intake had a lower risk of ALF than the reference group (0.14 (0.03–0.64) in high-risk alcohol drinkers and 0.11 (0.05–0.25) in low-risk alcohol drinkers).

conclusionsHigh coffee intake was associated with a low risk of liver fibrosis even in HIV-HCV co-infected patients with high-risk alcohol consumption.

Indexed as

AdultAlcohol DrinkingBiomarkersCoffeeCohort StudiesDisease ProgressionFemaleFranceHepatitis C, ChronicHIV InfectionsHumansLiverLiver CirrhosisLongitudinal StudiesMaleMiddle AgedBiomarkersCoffeealcohol consumptioncoffeeHIV-HCV co-infectionliver fibrosis

Identifiers

PMID29857547
PMCPMC6024311
OpenAlexW2806780414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.